GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Shareholder Yield %

CDTX (Cidara Therapeutics) Shareholder Yield % : -101.70% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Cidara Therapeutics's Shareholder Yield % was -101.70%.


Cidara Therapeutics Shareholder Yield % Historical Data

The historical data trend for Cidara Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Shareholder Yield % Chart

Cidara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -4.39 -171.65 1.78 -2.09

Cidara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 -2.09 -3.67 -1,758.37 -1.63

Competitive Comparison of Cidara Therapeutics's Shareholder Yield %

For the Biotechnology subindustry, Cidara Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Shareholder Yield % falls into.



Cidara Therapeutics Shareholder Yield % Calculation

Cidara Therapeutics's Shareholder Yield % for the quarter that ended in Sep. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+0.57 %+-2.2 %
=-1.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Cidara Therapeutics  (NAS:CDTX) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Cidara Therapeutics Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121

Cidara Therapeutics Headlines

From GuruFocus